Taysha Gene Therapies Inc... (TSHA)
Taysha Gene Therapies Inc. (TSHA) Stock Price, Analysis & Data
| Bid | 4.64 |
| Market Cap | 1.84B |
| Revenue (ttm) | 7.47M |
| Net Income (ttm) | -129.88M |
| Beta | 1.19 |
| EPS (ttm) | -0.41 |
| PE Ratio (ttm) | n/a |
| Forward PE | -13.77 |
| P/B (ttm) | 8.68 |
| P/S (ttm) | 246.36 |
| Earnings Date | Nov 4, 2026 |
| Ask | 7.8 |
| Volume | 3,913,776 |
| Avg. Volume (20D) | 3,101,453 |
| Open | 6.13 |
| Previous Close | 6.68 |
| Day's Range | 6.01 - 6.45 |
| 52-Week Range | 2.71 - 7.30 |
| Analyst | Strong Buy |
| Price Target | 12.5 (95.01%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TSHA
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease...
Financial Performance
In 2025, Taysha Gene Therapies's revenue was 9.77M, an increase of 17.28% compared to the previous year's 8.33M. Earnings were -109M, an increase of 22.06%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for TSHA stock is "Strong Buy". The 12-month stock price forecast is 12.5, which is upside of 95.01% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
